Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Athebio AG has 2 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 2 distinct examiners across 2 distinct art units, placing each pending matter in a separate examination assignment.
COFFA, SERGIO is the busiest examiner with 1 pending action. Because the docket is divided evenly between examiners, counsel should tailor each response while maintaining a consistent position on related biotechnology claim scope.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| COFFA, SERGIO | 1 | 61.1% | +32.3% |
| TSUI, YUNG-SHENG M | 1 | 66.5% | +6.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18633283 | N-Terminal Capping Modules of Ankyrin Repeat Domains | COFFA, SERGIO | 86d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18633283 | N-Terminal Capping Modules of Ankyrin Repeat Domains | COFFA, SERGIO | 86d overdue |
| Art Unit | Apps |
|---|---|
| 1658 | 1 |
| 1684 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18633283 | N-Terminal Capping Modules of Ankyrin Repeat Domains | COFFA, SERGIO | 1658 | §102§103§112 | Non-Final OA | 86d overdue | Pending | Apr 11, 2024 |
| 18442492 | Variants of Ankyrin Repeat Domains | TSUI, YUNG-SHENG M | 1684 | §112DP | Non-Final OA | — | Pending | Feb 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAthebio AG has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Sergio Coffa has the most, with 1 of Athebio AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
